Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00530855 · ClinicalTrials.gov registry record · Phase 3
Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 322
- Enrollment target
NCT00530855 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 322 participants.
The verdict
NCT00530855, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 322 participants
- Enrollment target
Study Summary
This open-label extension trial will assess the long-term use of Lacosamide monotherapy and safety of Lacosamide monotherapy and adjunctive therapy in subjects with partial-onset seizures who were previously enrolled in the conversion to monotherapy trial (SP902).
Interventions
- DRUG Lacosamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 322 participants |
| Start Date | 2008-02 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00530855
The ClinicalTrials.gov registry entry for NCT00530855 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 322 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lacosamide is the first listed.
NCT00530855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00530855 about?
NCT00530855 is a clinical study titled "Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures". This open-label extension trial will assess the long-term use of Lacosamide monotherapy and safety of Lacosamide monotherapy and adjunctive therapy in subjects with partial-onset seizures who were previously enrolled in the conversion to monotherapy trial (SP902).
What is the current status of trial NCT00530855?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 322 participants. The study started on 2008-02. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00530855?
The interventions under investigation include: Lacosamide (DRUG).
Who is sponsoring clinical trial NCT00530855?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.